- Home
- MCRB
MCRB
Seres Therapeutics Inc.
as 11-20-2024 4:00pm EST
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 2015 |
| Target Price: | $5.63 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $2.05 | Next Earning Date: | 11-13-2024 |
| Revenue: | $126,325,000 | Revenue Growth: | -0.72% |
| Revenue Growth (this year): | -96.42% | Revenue Growth (next year): | 215.76% |
Stock Insider Trading Activity of Seres Therapeutics Inc. (MCRB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Young Teresa L. | MCRB | See Remarks | Nov 15 '24 | Sell | $0.54 | 735 | $397.64 | 90,404 | |
| DesRosier Thomas | MCRB | Chief Legal Officer and EVP | Nov 15 '24 | Sell | $0.54 | 878 | $474.73 | 135,192 | |
| von Moltke Lisa | MCRB | See Remarks | Nov 15 '24 | Sell | $0.54 | 977 | $528.26 | 32,415 | |
| Shaff Eric D. | MCRB | CEO and President | Nov 15 '24 | Sell | $0.54 | 2,505 | $1,354.95 | 170,389 | |
| Henn Matthew R. | MCRB | See Remarks | Nov 15 '24 | Sell | $0.54 | 927 | $501.23 | 77,770 | |
| Young Teresa L. | MCRB | See Remarks | Oct 27 '24 | Sell | $0.69 | 2,983 | $2,058.57 | 90,404 | |
| von Moltke Lisa | MCRB | See Remarks | Oct 27 '24 | Sell | $0.69 | 4,334 | $2,991.33 | 32,415 | |
| Shaff Eric D. | MCRB | CEO and President | Oct 27 '24 | Sell | $0.69 | 8,748 | $6,036.99 | 170,389 | |
| Henn Matthew R. | MCRB | See Remarks | Oct 27 '24 | Sell | $0.69 | 3,984 | $2,749.36 | 77,770 |
Latest Seres Therapeutics Inc. News
MCRB Breaking Stock News: Dive into MCRB Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)
GuruFocus.com
7 days ago
Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...
Associated Press Finance
8 days ago
Seres Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
8 days ago
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
15 days ago
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
MT Newswires
a month ago
JPMorgan Downgrades Seres Therapeutics to Underweight
Simply Wall St.
a month ago
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value
MT Newswires
2 months ago
Seres Therapeutics Files Registration for Resale of Shares by Societe des Produits Nestle
Compare MCRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MCRB Seres Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.